Publication highlights Deramiocel’s anti-fibrotic activity and describes a validated potency assay supporting quality control ...
Capricor Therapeutics (CAPR) announced the publication in Biomedicines, an international peer-reviewed journal, describing a novel in-vitro ...
Company to Host Conference Call on November 10, 2025, at 4:30 p.m. ETSAN DIEGO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Capricor ...
Zacks Investment Research on MSN
Capricor (CAPR) Moves 12.0% Higher: Will This Strength Last?
Capricor Therapeutics (CAPR) shares soared 12% in the last trading session to close at $6.92. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...
Lizzy Lawrence leads STAT’s coverage of the Food and Drug Administration. She was previously a medical devices reporter. You can reach Lizzy on Signal at lizzylaw.53. BOSTON — Replimune Group and ...
LOS ANGELES, Sept. 09, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) investors of a class action representing investors ...
Capricor Therapeutics finds itself navigating turbulent waters as a federal securities class action lawsuit casts uncertainty over the company's future. The legal investigation, made public on October ...
(RTTNews) - Biotechnology company Capricor Therapeutics (CAPR) Thursday announced the completion of the submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration ...
High-rolling investors have positioned themselves bearish on Capricor Therapeutics (NASDAQ:CAPR), and it's important for retail traders to take note. \This activity came to our attention today through ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback